Bruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.
Bruno Delagneau
Advertisement
Bruno Delagneau, M.D. is currently a consultant for pharmaceutical and biotech companies. He is the former CEO and founder of Idekos, a privately funded biotech company and a former Vice President at Gilead Sciences.
Articles by Bruno Delagneau
Advertisement
Latest Updated Articles
Is the Price Right Figure 2October 1st 2018
Is the Price Right? An Overview of US Pricing StrategiesNovember 1st 2018
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
2
Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals
3
When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
4
JCA vs. Reality: Europe’s Push for Clinical Harmonization
5